Latest Insights - page 46 | BiopharmaTrend

Citryll Secures €85M to Advance Monoclonal Antibody Targeting NETs in Inflammatory Diseases

Citryll, a biotechnology company focused on developing monoclonal antibody therapies to address immune-mediated inflammatory diseases, has completed an €85 million Series B financing round. The round was co-led by Johnson …

Continue ›››

The AI-driven Development Journey of ISM5411, a Potential Breakthrough Treatment for Inflammatory Bowel Disease

Inflammatory Bowel Disease (IBD), a chronic and debilitating autoimmune disorder that includes ulcerative colitis and Crohn’s disease, impacts millions of lives globally. Characterized by chronic gut inflammation, intestinal barrier dysfunction, …

Continue ›››

Chroma Medicine and Nvelop Therapeutics Merge to Form nChroma Bio with $75 Million Financing

Chroma Medicine and Nvelop Therapeutics have announced their merger to form nChroma Bio, a new biotechnology company focused on advancing genetic medicines. Alongside the merger, nChroma secured $75 million in …

Continue ›››

DASA Launches Microbial Forensics Competition to Enhance UK Biosecurity

The Defence and Security Accelerator (DASA), in partnership with the Defence Science and Technology Laboratory (Dstl), has launched a new themed competition titled "Future-proofing Biosecurity by Strengthening the UK’s Microbial …

Continue ›››

Tasca Therapeutics Launches with $52 Million to Advance Precision Oncology

Tasca Therapeutics, a biotechnology company focused on small molecule inhibitors for oncology, has raised $52 million in Series A financing. The round was co-led by Regeneron Ventures and Cure Ventures, …

Continue ›››

Dot Compliance Expands AI Capabilities to Transform Quality and Compliance in Life Sciences

Dot Compliance, a provider of AI-powered compliance and electronic quality management system (eQMS) solutions, has introduced the third generation of its AI technology. These upgrades aim to make quality and …

Continue ›››

Cradle Achieves 8x Improved EGFR Binding Over Merck’s Cetuximab in Protein Design Challenge

Cradle’s platform has achieved first place in Adaptyv Bio's protein design competition by producing a novel EGFR-binding protein with a binding affinity of 1.21 nM, outperforming Merck’s Cetuximab (9.94 nM) …

Continue ›››

The Importance of Accurate Patient Matching for AI Projects

Artificial intelligence (AI) is revolutionizing healthcare by enhancing workflows, enabling earlier diagnoses, and paving the way for personalized care. However, its success depends on accurate patient matching, which ensures data …

Continue ›››

AQEMIA Reaches $100 Million in Funding, Plans Expansion and Prepares for Clinical Trials

AQEMIA, a techbio company teaching atomic scale physics to a generative AI, has announced reaching $100 million in cumulative funding. The milestone coincides with plans for global expansion, starting with …

Continue ›››

Recursion Reports Encouraging Interim Phase 1 Data a Selective CDK7 Inhibitor

Recursion (Nasdaq: RXRX) announced interim findings from the ongoing Phase 1/2 ELUCIDATE trial evaluating REC-617, a precision-designed, oral CDK7 inhibitor developed to address common resistance pathways in advanced solid tumors. …

Continue ›››

BioAge Labs Halts STRIDES Phase 2 Trial of Azelaprag-Tirzepatide Combo

BioAge Labs, which recently raised upwards of $198 million through an upsized IPO in September 2024 to fund its clinical trials, has announced the discontinuation of its STRIDES Phase 2 …

Continue ›››

Vittoria Biotherapeutics Highlights Novel CAR-T Cell Therapy Approach at ASH 2024

Vittoria Biotherapeutics, a Philadelphia-based clinical-stage immunotherapy company, showcased preclinical findings at the 66th Annual American Society of Hematology (ASH) Meeting.

Continue ›››